EUCTR2013-000192-33-BE进行中（未招募）不适用
A Multicenter, Multiple-dose, Two-arm, Active-controlled, Double-blind, Double-dummy Study to Compare the Therapeutic Efficacy and Safety of Oral Doses of Cinacalcet HCl With Intravenous Doses of AMG 416 in HemodialysisSubjects With Secondary Hyperparathyroidism
KAI Pharmaceuticals, Inc (a subsidiary of Amgen, Inc.)0 个研究点目标入组 600 人开始时间: 2013年6月7日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 600
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- Subject has provided informed consent.
- •- Subject is 18 years of age or older.
- •- Female subject must be willing to use highly effective contraception during the study and for 3 months after the last dose of investigational product (unless postmenopausal or surgically sterilized).
- •- Subject must be receiving maintenance hemodialysis 3 times weekly for at least 3 months, with adequate hemodialysis with a delivered Kt/V= 1.2 or urea reduction ratio (URR) = 65% within 4 weeks prior to screening laboratory assessments.
- •- Dialysate calcium concentration must be = 2.5 mEq/L and stable for at least 4 weeks prior to screening laboratory assessments, and must remain = 2.5 mEq/L for the duration of the study.
- •- Subject must have SHPT as defined by one central laboratory screening predialysis serum PTH value > 500 pg/mL, within 2 weeks prior to randomization.
- •- Subject currently receiving vitamin D sterols must have had no more than a maximum dose change of 50% within the 4 weeks prior to screening laboratory assessments, remain stable through
- •randomization, and be expected to maintain stable doses for the
- •duration of the study, except for adjustments allowed per protocol.
- •- Subject must have one screening predialysis serum cCa laboratory value = 8.3 mg/dL measured within 2 weeks prior to randomization.
- •- A subject receiving calcium supplements must have had no more than a maximum dose change of 50% within 2 weeks prior to screening laboratory assessments and remain stable through randomization.
- •- A subject receiving phosphate binders must have had no more than a maximum dose change of 50% within the 2 weeks prior to screening laboratory assessments, remain stable through randomization, and be expected to maintain stable dose for the duration of the study, except for adjustments allowed per protocol.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 600
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •- Currently receiving treatment in another investigational device or drug study, or less than 30 days since ending treatment on another investigational device or drug study(s).
- •- Currently receiving other investigational procedures while participating in this study are excluded.
- •- Subject has received AMG 416 in a prior clinical trial of AMG 416 (also known as KAI-4169).
- •- Subject has received cinacalcet during the 3 months prior to the first screening laboratory assessments.
- •- Subject has known sensitivity to any of the products or components of either cinacalcet or AMG 416 to be administered during dosing.
- •- Subject has previously been randomized this study
- •- Anticipated or scheduled parathyroidectomy during the study period.
- •- Subject has received a parathyroidectomy within 6 months prior to dosing.
- •- Anticipated or scheduled kidney transplant during the study period.
- •- Subject has an unstable medical condition based on medical history, physical examination, and routine laboratory tests, or is otherwise unstable in the judgment of the Investigator.
- •- Malignancy within the last 5 years (except non-melanoma skin cancers or cervical carcinoma in situ).
- •- Subject is pregnant or nursing.
- •- Subject has a history of symptomatic ventricular dysrhythmias or Torsades de Pointes.
- •- Subject has a history of myocardial infarction, coronary angioplasty, or coronary arterial bypass grafting within the past 6 months prior to screening.
- •- Subject has clinically significant abnormalities on prestudy clinical examination or abnormalities on the most recent central laboratory tests during the screening period prior to randomization according to the Investigator including but not
- •limited to the following:
- •serum albumin < 2.5 g/dL
- •serum magnesium < 1.5 mg/dL
- •serum transaminase (alanine transaminase [ALT] or Serum glutamic pyruvic transaminase [SGPT], aspartate aminotransferase [AST] or serum glutamic oxaloacetic transaminase [SGOT]) > 2.5 times the upper limit of normal (ULN) at screening
- •- Subject likely to not be available to complete all protocol-required study visits or procedures, and/or to comply with all required study procedures to the best of the subject and Investigator’s knowledge.
- •- History or evidence of any other clinically significant disorder, condition or disease (with the exception of those outlined above) that, in the opinion of the Investigator or Amgen physician, if consulted, would pose a risk to subject safety or interfere with the study evaluation, procedures or completion. This includes a subject who previously received cinacalcet, and in the opinion of the Investigator, is not a good candidate for future cinacalcet treatment.
研究者
相似试验
进行中（未招募）
不适用
Compare therapeutic efficacy and safey of AMG 416 and cinacalcet HCl in hemodialysis subjects with secondary hyperparathyroidismChronic Kidney DiseaseSecondary Hyperparathyroidism (SHPT)MedDRA version: 17.1Level: LLTClassification code 10064848Term: Chronic kidney diseaseSystem Organ Class: 100000004857MedDRA version: 17.1Level: PTClassification code 10020708Term: Hyperparathyroidism secondarySystem Organ Class: 10014698 - Endocrine disordersEUCTR2013-000192-33-DKKAI Pharmaceuticals, Inc (a subsidiary of Amgen, Inc.)600
进行中（未招募）
不适用
Compare therapeutic efficacy and safey of AMG 416 and cinacalcet HCl in hemodialysis subjects with secondary hyperparathyroidismChronic Kidney DiseaseSecondary Hyperparathyroidism (SHPT)MedDRA version: 14.1Level: LLTClassification code 10064848Term: Chronic kidney diseaseSystem Organ Class: 100000004857MedDRA version: 14.1Level: PTClassification code 10020708Term: Hyperparathyroidism secondarySystem Organ Class: 10014698 - Endocrine disordersEUCTR2013-000192-33-LVKAI Pharmaceuticals, Inc (a subsidiary of Amgen, Inc.)600
进行中（未招募）
不适用
Compare therapeutic efficacy and safey of AMG 416 and cinacalcet HCl in hemodialysis subjects with secondary hyperparathyroidismEUCTR2013-000192-33-ATKAI Pharmaceuticals, Inc (a subsidiary of Amgen, Inc.)600
进行中（未招募）
1 期
Compare therapeutic efficacy and safey of AMG 416 and cinacalcet HCl in hemodialysis subjects with secondary hyperparathyroidismEUCTR2013-000192-33-DEKAI Pharmaceuticals, Inc (a subsidiary of Amgen, Inc.)600
进行中（未招募）
不适用
Compare therapeutic efficacy and safey of AMG 416 and cinacalcet HCl in hemodialysis subjects with secondary hyperparathyroidismChronic Kidney DiseaseSecondary Hyperparathyroidism (SHPT)MedDRA version: 17.1Level: LLTClassification code 10064848Term: Chronic kidney diseaseSystem Organ Class: 100000004857MedDRA version: 17.1Level: PTClassification code 10020708Term: Hyperparathyroidism secondarySystem Organ Class: 10014698 - Endocrine disordersEUCTR2013-000192-33-EEKAI Pharmaceuticals, Inc (a subsidiary of Amgen, Inc.)600